Ghia, P., Eichhorst, B., Wróbel, T., Alacacıoğlu, I., Fonseca, A. R. D., Carney, D., Cartron, G., Gerrie, A., Stevens, D., Borja, M. D., Fujimori, T., John, E., Liggett, L. A., Jesus, G. D., Munugalavadla, V., Brown, J. (2025). Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY. Blood. https://doi.org/10.1182/blood-2025-3898